Which has stronger earnings and valuation, CGON or ANAB?

AnaptysBio has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $6.23M 1,044.10 -$160.99M -$2.69 N/A AnaptysBio $234.60M 6.41 -$13.23M $5.37 9.45

Is CGON or ANAB more profitable?

AnaptysBio has a net margin of 82.37% compared to CG Oncology's net margin of -3,602.68%. AnaptysBio's return on equity of 112.00% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology -3,602.68% -25.20% -23.98% AnaptysBio 82.37% 112.00% 2.20%

Does the media refer more to CGON or ANAB?

In the previous week, AnaptysBio had 13 more articles in the media than CG Oncology. MarketBeat recorded 19 mentions for AnaptysBio and 6 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.88 beat AnaptysBio's score of 0.52 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ORKA or ANAB?

In the previous week, AnaptysBio had 4 more articles in the media than Oruka Therapeutics. MarketBeat recorded 19 mentions for AnaptysBio and 15 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.54 beat AnaptysBio's score of 0.52 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or ANAB?

In the previous week, AnaptysBio had 15 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 19 mentions for AnaptysBio and 4 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.72 beat AnaptysBio's score of 0.52 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is SRRK or ANAB more profitable?

AnaptysBio has a net margin of 82.37% compared to Scholar Rock's net margin of 0.00%. AnaptysBio's return on equity of 112.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% AnaptysBio 82.37% 112.00% 2.20%

Does the media refer more to SRRK or ANAB?

In the previous week, AnaptysBio had 3 more articles in the media than Scholar Rock. MarketBeat recorded 19 mentions for AnaptysBio and 16 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.76 beat AnaptysBio's score of 0.52 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TVTX or ANAB?

In the previous week, Travere Therapeutics had 24 more articles in the media than AnaptysBio. MarketBeat recorded 43 mentions for Travere Therapeutics and 19 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.52 beat Travere Therapeutics' score of 0.27 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 15 Very Positive mention(s) 10 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AnaptysBio 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

AnaptysBio (ANAB) Competitors

$50.77 -3.15 (-5.84%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$50.82 +0.04 (+0.09%)

As of 09/23/2026 07:30 PM Eastern

Compare

ANAB vs. CGON, ORKA, MIRM, SRRK, and TVTX

Should you buy AnaptysBio stock or one of its competitors? AnaptysBio's main competitors and comparable companies include CG Oncology (CGON), Oruka Therapeutics (ORKA), Mirum Pharmaceuticals (MIRM), Scholar Rock (SRRK), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AnaptysBio compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and AnaptysBio (NASDAQ:ANAB) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

26.6% of CG Oncology shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 31.5% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CG Oncology has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market.

AnaptysBio has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$6.23M	1,044.10	-$160.99M	-$2.69	N/A
AnaptysBio	$234.60M	6.41	-$13.23M	$5.37	9.45

CG Oncology currently has a consensus target price of $87.78, suggesting a potential upside of 19.65%. AnaptysBio has a consensus target price of $79.15, suggesting a potential upside of 55.91%. Given AnaptysBio's higher probable upside, analysts plainly believe AnaptysBio is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

AnaptysBio has a net margin of 82.37% compared to CG Oncology's net margin of -3,602.68%. AnaptysBio's return on equity of 112.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
AnaptysBio	82.37%	112.00%	2.20%

In the previous week, AnaptysBio had 13 more articles in the media than CG Oncology. MarketBeat recorded 19 mentions for AnaptysBio and 6 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.88 beat AnaptysBio's score of 0.52 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AnaptysBio beats CG Oncology on 12 of the 16 factors compared between the two stocks.

How does AnaptysBio compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and AnaptysBio (NASDAQ:ANAB) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Oruka Therapeutics presently has a consensus price target of $133.00, indicating a potential upside of 47.89%. AnaptysBio has a consensus price target of $79.15, indicating a potential upside of 55.91%. Given AnaptysBio's higher possible upside, analysts plainly believe AnaptysBio is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

56.4% of Oruka Therapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 31.5% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Oruka Therapeutics has a beta of -0.34, meaning that its share price is 134% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

AnaptysBio has a net margin of 82.37% compared to Oruka Therapeutics' net margin of 0.00%. AnaptysBio's return on equity of 112.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
AnaptysBio	82.37%	112.00%	2.20%

In the previous week, AnaptysBio had 4 more articles in the media than Oruka Therapeutics. MarketBeat recorded 19 mentions for AnaptysBio and 15 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.54 beat AnaptysBio's score of 0.52 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	5 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

AnaptysBio has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
AnaptysBio	$234.60M	6.41	-$13.23M	$5.37	9.45

Summary

AnaptysBio beats Oruka Therapeutics on 12 of the 15 factors compared between the two stocks.

How does AnaptysBio compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and AnaptysBio (NASDAQ:ANAB) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Mirum Pharmaceuticals has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

Mirum Pharmaceuticals presently has a consensus price target of $137.31, suggesting a potential upside of 53.73%. AnaptysBio has a consensus price target of $79.15, suggesting a potential upside of 55.91%. Given AnaptysBio's higher possible upside, analysts plainly believe AnaptysBio is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

AnaptysBio has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$618.07M	9.38	-$23.36M	-$14.55	N/A
AnaptysBio	$234.60M	6.41	-$13.23M	$5.37	9.45

In the previous week, AnaptysBio had 15 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 19 mentions for AnaptysBio and 4 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.72 beat AnaptysBio's score of 0.52 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

AnaptysBio has a net margin of 82.37% compared to Mirum Pharmaceuticals' net margin of -139.18%. AnaptysBio's return on equity of 112.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
AnaptysBio	82.37%	112.00%	2.20%

Summary

AnaptysBio beats Mirum Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does AnaptysBio compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and AnaptysBio (NASDAQ:ANAB) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

AnaptysBio has a net margin of 82.37% compared to Scholar Rock's net margin of 0.00%. AnaptysBio's return on equity of 112.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
AnaptysBio	82.37%	112.00%	2.20%

91.1% of Scholar Rock shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by company insiders. Comparatively, 31.5% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

AnaptysBio has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
AnaptysBio	$234.60M	6.41	-$13.23M	$5.37	9.45

Scholar Rock currently has a consensus price target of $66.69, suggesting a potential upside of 33.78%. AnaptysBio has a consensus price target of $79.15, suggesting a potential upside of 55.91%. Given AnaptysBio's higher possible upside, analysts clearly believe AnaptysBio is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	2.94
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

In the previous week, AnaptysBio had 3 more articles in the media than Scholar Rock. MarketBeat recorded 19 mentions for AnaptysBio and 16 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.76 beat AnaptysBio's score of 0.52 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

Summary

AnaptysBio beats Scholar Rock on 12 of the 16 factors compared between the two stocks.

How does AnaptysBio compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and AnaptysBio (NASDAQ:ANAB) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

AnaptysBio has a net margin of 82.37% compared to Travere Therapeutics' net margin of -7.35%. AnaptysBio's return on equity of 112.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
AnaptysBio	82.37%	112.00%	2.20%

AnaptysBio has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$591.33M	9.54	-$25.55M	-$0.46	N/A
AnaptysBio	$234.60M	6.41	-$13.23M	$5.37	9.45

Travere Therapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

In the previous week, Travere Therapeutics had 24 more articles in the media than AnaptysBio. MarketBeat recorded 43 mentions for Travere Therapeutics and 19 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.52 beat Travere Therapeutics' score of 0.27 indicating that AnaptysBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	15 Very Positive mention(s)	10 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AnaptysBio	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics presently has a consensus price target of $68.10, suggesting a potential upside of 13.82%. AnaptysBio has a consensus price target of $79.15, suggesting a potential upside of 55.91%. Given AnaptysBio's higher probable upside, analysts clearly believe AnaptysBio is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

AnaptysBio beats Travere Therapeutics on 9 of the 14 factors compared between the two stocks.

Get AnaptysBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANAB vs. The Competition

Export

Metric	AnaptysBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.60B	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	9.45	13.88	274.08	25.69
Price / Sales	6.41	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	37.89	15.40	10.47	6.32
Net Income	-$13.23M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-7.79%	-1.70%	-0.67%	0.17%
1 Month Performance	-13.12%	-6.17%	-3.17%	-3.27%
1 Year Performance	129.31%	30.67%	15.14%	5.58%

AnaptysBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANAB AnaptysBio	3.4539 of 5 stars	$50.77 -5.8%	$79.15 +55.9%	+142.3%	$1.60B	$234.60M	9.45	104	News Coverage Earnings Report Analyst Forecast
CGON CG Oncology	3.0275 of 5 stars	$74.12 +2.2%	$87.78 +18.4%	+99.9%	$6.43B	$4.04M	N/A	142
ORKA Oruka Therapeutics	3.7492 of 5 stars	$93.55 +1.5%	$133.00 +42.2%	+478.0%	$6.10B	N/A	N/A	68	Trending News
MIRM Mirum Pharmaceuticals	3.0776 of 5 stars	$97.37 +3.7%	$137.31 +41.0%	+21.3%	$6.10B	$521.31M	N/A	433	High Trading Volume
SRRK Scholar Rock	3.4856 of 5 stars	$49.37 -1.3%	$66.00 +33.7%	+47.7%	$6.09B	N/A	N/A	289	Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANAB) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AnaptysBio (ANAB) Competitors

ANAB vs. CGON, ORKA, MIRM, SRRK, and TVTX

How does AnaptysBio compare to CG Oncology?

Summary

How does AnaptysBio compare to Oruka Therapeutics?

Summary

How does AnaptysBio compare to Mirum Pharmaceuticals?

Summary

How does AnaptysBio compare to Scholar Rock?

Summary

How does AnaptysBio compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB vs. The Competition

AnaptysBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AnaptysBio (ANAB) Competitors

ANAB vs. CGON, ORKA, MIRM, SRRK, and TVTX

How does AnaptysBio compare to CG Oncology?

Do institutionals & insiders believe in CGON or ANAB?

Which has more volatility & risk, CGON or ANAB?

Which has stronger earnings and valuation, CGON or ANAB?

Do analysts prefer CGON or ANAB?

Is CGON or ANAB more profitable?

Does the media refer more to CGON or ANAB?

Summary

How does AnaptysBio compare to Oruka Therapeutics?

Do analysts recommend ORKA or ANAB?

Do insiders and institutionals have more ownership in ORKA or ANAB?

Which has more volatility & risk, ORKA or ANAB?

Is ORKA or ANAB more profitable?

Does the media refer more to ORKA or ANAB?

Which has stronger valuation and earnings, ORKA or ANAB?

Summary

How does AnaptysBio compare to Mirum Pharmaceuticals?

Which has more volatility and risk, MIRM or ANAB?

Do analysts rate MIRM or ANAB?

Which has better earnings & valuation, MIRM or ANAB?

Does the media prefer MIRM or ANAB?

Is MIRM or ANAB more profitable?

Summary

How does AnaptysBio compare to Scholar Rock?

Is SRRK or ANAB more profitable?

Do insiders and institutionals hold more shares of SRRK or ANAB?

Which has higher earnings and valuation, SRRK or ANAB?

Do analysts recommend SRRK or ANAB?

Does the media refer more to SRRK or ANAB?

Which has more risk and volatility, SRRK or ANAB?

Summary

How does AnaptysBio compare to Travere Therapeutics?

Is TVTX or ANAB more profitable?

Which has stronger earnings & valuation, TVTX or ANAB?

Which has more volatility and risk, TVTX or ANAB?

Does the media prefer TVTX or ANAB?

Do analysts recommend TVTX or ANAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB vs. The Competition

AnaptysBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools